For example, many current approaches for gene therapy in DMD aim to restore ‘short’ Dystrophins, known to be partially functional from studies of patients with BMD and murine transgenic models (Konieczny et al., 2013). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.